scholarly journals Search for the “ideal analgesic” in pain treatment by engineering the mu-opioid receptor

IUBMB Life ◽  
2009 ◽  
pp. NA-NA
Author(s):  
Pao-Luh Tao ◽  
Ping-Yee Law ◽  
Horace H. Loh
Keyword(s):  
Opioid Receptor ◽  
Pain Treatment ◽  
Mu Opioid Receptor ◽  
Mu Opioid

Sending out Biased Signals: an Appropriate Proposition for Pain?

2019 ◽  
Vol 32 (2) ◽  
pp. 108-110 ◽  
Author(s):  
E. Besserer-Offroy ◽  
P. Sarret
Keyword(s):  
Side Effects ◽  
Acute Pain ◽  
Gold Standard ◽  
Pain Treatment ◽  
Opioid Analgesics ◽  
Mu Opioid Receptor ◽  
Clinical Development ◽  
Mu Opioid ◽  
Development Stages ◽  
The Past

In the past few years, several biased ligands acting at the mu-opioid receptor were reported in the literature. These agonists are aimed at reducing pain while having fewer side effects than morphine, the gold standard of opioid analgesics. In this mini-review, we describe and discuss the recent advances in mu-biased ligands actually in preclinical and clinical development stages, including the latest U.S. Food and Drug Administration review of oliceridine, a biased mu-agonist for moderate to severe acute pain treatment developed by the company Trevena.

scholarly journals Variation of the human mu-opioid receptor (OPRM1) gene predicts vulnerability to frustration

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Alan M. Daniel ◽  
Brenda G. Rushing ◽  
Karla Y. Tapia Menchaca
Keyword(s):  
Individual Differences ◽  
Animal Models ◽  
Opioid Receptor ◽  
Receptor Gene ◽  
Emotional Reaction ◽  
Mu Opioid Receptor ◽  
Reward Processing ◽  
Physical Pain ◽  
Mu Opioid ◽  
Allelic Differences

AbstractUnderstanding the emotional reaction to loss, or frustration, is a critical problem for the field of mental health. Animal models of loss have pointed to the opioid system as a nexus of frustration, physical pain, and substance abuse. However, few attempts have been made to connect the results of animal models of loss to human behavior. Allelic differences in the human mu opioid receptor gene, notably the A118G single nucleotide polymorphism, have been linked to individual differences in pain sensitivity, depressive symptoms, and reward processing. The present study explored the relationship between A118G and behavior in two frustrating tasks in humans. Results showed that carriers of the mutant G-allele were slower to recover behavior following a reward downshift and abandoned a frustrating task earlier than those without the mutation. Additionally, G-carriers were more sensitive to physical pain. These results highlight the overlap between frustration and pain, and suggest that genetic variation in opioid tone may contribute to individual differences in vulnerability and resilience following emotional disturbances.

scholarly journals Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. VOLUME 280 (2005) PAGES 32618-32624

2005 ◽  
Vol 280 (46) ◽  
pp. 38888
Author(s):  
Ying Zhang ◽  
Danxin Wang ◽  
Andrew D. Johnson ◽  
Audrey C. Papp ◽  
Wolfgang Sadée
Keyword(s):  
Opioid Receptor ◽  
Mu Opioid Receptor ◽  
Allelic Expression ◽  
Allelic Expression Imbalance ◽  
Mu Opioid

scholarly journals Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice

2021 ◽  
Author(s):  
Yu‐Syuan Wang ◽  
Tsai‐Wei Hung ◽  
Eun‐Kyung Bae ◽  
Kuo‐Jen Wu ◽  
Wei Hsieh ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Opioid Receptor ◽  
Knockout Mice ◽  
Mu Opioid Receptor ◽  
Mu Opioid
Sign in / Sign up

Export Citation Format

Share Document